Effects of an orally active converting-enzyme inhibitor, SQ 14225, on pressor responses to angiotensin administered into the brain ventricles of spontaneously hypertensive rats.
暂无分享,去创建一个
D. Ganten | A. Schömig | R. Dietz | W. Rascher | J. Mann
[1] D. Ganten,et al. Effects of central and peripheral angiotensin blockade in hypertensive rats. , 1978, The American journal of physiology.
[2] B. Rubin,et al. SQ 14,225 (D-3-mercapto-2-methylpropanoyl-l-proline), a novel orally active inhibitor of angiotensin I-converting enzyme. , 1978, The Journal of pharmacology and experimental therapeutics.
[3] D. Ganten,et al. Lowering of hypertension by central saralasin in the absence of plasma renin , 1977, Nature.
[4] R. Vollmer,et al. Central cardiovascular effects of SQ 14,225, an angiotensin-converting enzyme inhibitor in chloralose-anesthetized cats. , 1977, European journal of pharmacology.
[5] B Rubin,et al. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. , 1977, Science.
[6] H. Gavras,et al. A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MAN , 1977, The Lancet.
[7] D. Ganten,et al. Interferences with the Renin-Angiotensin System and Their Effects on High Blood Pressure , 1977 .
[8] F. Graeff,et al. Central mechanisms of the hypertensive action of intraventricular bradykinin in the unanaesthetized rat. , 1974, Neuropharmacology.